Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN01194 in Advanced Solid Tumours
NCT06305247Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Apr 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of ipn01194 in solid tumor, melanoma, colorectal cancer (CRC) and 2 more (2 arms), sponsored by Ipsen. Primary endpoints: Dose Limiting Toxicity at 28 days, Treatment-Emergent Adverse Events and 2 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
ipn01194
03
Conditions
solid tumormelanomacolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06305247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305247.